Why is the price of Alpelisib attracting so much attention? Not yet available in the country, original Indian drugs and Laotian generic drugs may become new choices for patients

New hope for precision treatment of breast cancer, Apelvis has not yet been launched in China

2025In the middle of the year, the frontier of treatment for PIK3CA mutant breast cancer was mentioned again at several international cancer conferences, and one of the most interesting drugs is Alpelisib (Alpelisib). As the world's first targeted drug targeting PIK3CA mutations, Apelvis has not only been approved for use in Europe and the United States, but has also been included in NCCN breast cancer treatment guidelines. However, it is regrettable that this important drug has not yet been approved for marketing in mainland China.

This means that many domestic late-stage hormone receptor-positive (HR+), HER2-negative breast cancer patients who are diagnosed with PIK3CA mutations are still unable to use this targeted drug through regular channels, seriously affecting the optimization of treatment plans and the realization of personalized medicine.

But at the same time, some patients have also noticed the price fluctuations and generic drug channels of Apelvis in overseas markets, which have become a new focus of attention.

Apelix: The first targeted drug approved to treat PIK3CA mutated breast cancer

Alpelisib (Alpelisib), trade name Piqray, was developed by Novartis. It is an oral and selective PI3Kα inhibitor. It was released in 2019 5 month for the treatment of patients with HR-positive, HER2-negative, and PIK3CA PIK3CA mutations in advanced or metastatic breast cancer, who need to be used in combination with fulvestrant.

The drug specifically targets PIK3CA mutations that are common in breast cancer patients (accounting for about 40%), through precise inhibition of tumor cell metabolic pathways, significantly improve progression-free survival (PFS) and disease control rate. In clinical trials, the median PFS of patients treated with apelvis combined with fulvestrant reached 11 months, while that of the control group was only 5.7 months. The efficacy was nearly doubled.

Because of this, Apelvis attracted widespread attention from the global oncology community once it was launched, and was quickly included in recommendations by authoritative guidelines such as NCCN and ESMO. However, for Chinese patients, the most practical question is: how to buy it? How much? Is it worth buying?

It has not yet been launched in China, and the original research price is high

As of now (2025year7month), Apelvis has not yet received NMPA approval for marketing in mainland China. Even when the FDA approved it in 2019, some domestic breast cancer experts already called for "accelerating the introduction of PI3K inhibitors", but the actual approval has not yet been put on the agenda.

Therefore, domestic patients who want to use Apelvis can only use the following methods:

1. Going abroad for medical treatment: such as going to hospitals in Singapore, India, Hong Kong and other places to purchase original drugs;

2.Overseas Purchasing Agency/Drug Mutual Aid Platform: Some platforms provide overseas channel drug purchasing services, which carries certain risks;

3.Choose overseas generic drugs: the cost is lower, but the source and quality need to be screened.

At present, the Indian and Laotian versions of Apelvis have become affordable alternatives and have been accepted by some breast cancer patients.

Overseas price analysis of Apelvis: original research VS imitation

Currently, there are mainly the following versions of Apelvis drugs available for purchase on the global market:

1. Indian original drug (manufactured by Novartis)

The original drug produced by Novartis has been launched in the Indian marketPiqray. Due to lower manufacturing costs and policy support, the price is much cheaper than in European and American markets. According to patients, the price of a box of Apelvis (specification: 28 tablets/box) is about 3000 RMB, which is currently the most cost-effective original research version. It is suitable for patients who pursue quality assurance and have moderate financial ability.

2. Lao generic version

Lao pharmaceutical companies have copied a variety of international cutting-edge targeted drugs in recent years, and Apelvis is one of them. This version is consistent with the original drug in terms of ingredients and dosage design. It has also appeared in many Asian markets after undergoing quality testing abroad.

Currently, the price per box of the Lao version of Apelvis is only 1,000 multiple yuan, which is suitable for long-term use by breast cancer patients with greater economic pressure. Cost control is more important for those who need maintenance treatment, especially.

It should be noted that patients must purchase through regular cross-border pharmacies or platform channels with word-of-mouth guarantees to avoid purchasing fake drugs or inferior imitations.

Why is the price of Apelvis so “diving”?

The R&D costs of original drugs are high and the brand premium is significant, resulting in prices generally in the tens of thousands of yuan per box in European and American markets.

The Indian and Laos versions follow the "affordable route", manufacturing costs are properly controlled, and the core strategy is to expand patient accessibility;

There is no China listing approval cost, further reducing circulation costs;

The cross-border purchasing model reduces the middleman layer, allowing patients to directly connect with overseas pharmacies and making prices more transparent.

Therefore, the price has dropped from the original high levelThe "diving" into the range of several thousand yuan and one thousand yuan for generic versions is the result of the current trend of drug globalization and the popularity of generic drugs.

Is Apelix worth buying? Which Patients Should Consider Medication

According toNCCN guidelines and clinical evidence, the following patients are more suitable to consider apelvis treatment:

1.HRpositive, HER2negative, breast cancer patients carrying PIK3CA mutation;

2.Resistant to frontlineCDK4/6 inhibitors (such as palbociclib, abeciclib) or endocrine therapy;

3.Medium-to-late-stage patients who have a strong willingness to undergo genetic testing and precise treatment;

4.Those who need to control the disease for a long time, delay the time of chemotherapy, and maintain the quality of life.

For those whose PIK3CA mutation status is not yet clear, it is recommended to first determine the mutation type through genetic testing before deciding whether to purchase drugs.

Apelix’s side effects and precautions

Although the efficacy of Apelvis is clear, there are also some common adverse reactions:

1.Hyperglycemia: the most common, blood sugar needs to be monitored and hypoglycemic drugs used if necessary;

2.Diarrhea, nausea, and loss of appetite: affect quality of life;

3.Skin rash and stomatitis: reported by about10-20% of patients;

4.Weight loss, fatigue, etc.

During the use of Apelvis, it is recommended to regularly monitor blood sugar, liver function and general blood routine indicators, and pay attention to individualized dosage adjustments. For patients with diabetes, they should communicate with their endocrinologist before taking medication.

The price advantage of Apelvis is highlighted, but we still need to be wary of the risks of counterfeit drugs

Currently, as the Indian and Lao versions gradually enter the horizons of Chinese patients, the "drug threshold" of Apelvis has been significantly lowered. However, while patients are paying attention to price, they also need to be wary of the following points:

1.Avoid purchasing drugs through unlicensed purchasing agents or private channels;

2.Choose a third-party overseas pharmacy or platform with a guaranteed reputation;

3. Communicate with the attending doctor in advance to confirm whether the treatment plan is suitable for you;

4. Pay attention to checking the drug batch number, production date, and packaging integrity to prevent the purchase of counterfeit drugs.

Apelix is undoubtedly a game-changer in the molecular era of breast cancer treatment. It brings new hope to some HR+/HER2- patients who are resistant to traditional regimens. Although it has not yet been launched in China, with the price advantage and quality assurance of the Indian and Laos versions, more and more patients are completing their medication goals through legal and compliant channels.

If you or your relatives are PIK3CA mutated breast cancer patients, you may wish to communicate with your doctor to understand the feasibility of genetic testing and overseas medication. Perhaps this is the most critical "accurate choice" in your life.

xa0

References:

1.Novartis official website – Piqray (Apelix) drug information: https://www.novartis.com/

2.FDA approval summary: Alpelisib + Fulvestrant in PIK3CA-mutated HR+/HER2- breast cancer（2019）

3.NCCN Guidelines: Breast Cancer 2024（HR+/HER2- management）